Novartis Faces More Than Fine In Japan Probe Of Drug-Ad Violations
This article was originally published in PharmAsia News
Novartis apparently faces more problems in Japan than a requested prosecutorial probe into its allegedly erroneous advertisements for its Diovan (valsartan).
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.